Prevent bleeding in kids with Hemophilia A who play sports
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/legal guardian) can give written consent, and you can agree if you’re a minor
- You’re age 6 to under 20 and have moderate to severe Hemophilia A (very low factor VIII activity) without inhibitors
- You are already using either emicizumab or standard factor VIII preventive treatment
- You are doing—or plan to start—sports that are rated moderate to high risk for bleeding
- You must be willing to keep detailed logs of sports activity, bleeding events, and treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
This trial compares two low-dose prophylactic treatments for severe hemophilia A. Patients receive either low-dose emicizumab or low-dose factor VIII to see which works better for preventing bleeding episodes.
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.